MX2017003808A - Una combinacion de quinurenina y celulas presentadoras de antigeno (apc) como productos terapeuticos y metodos para uso en modulacion inmunitaria. - Google Patents

Una combinacion de quinurenina y celulas presentadoras de antigeno (apc) como productos terapeuticos y metodos para uso en modulacion inmunitaria.

Info

Publication number
MX2017003808A
MX2017003808A MX2017003808A MX2017003808A MX2017003808A MX 2017003808 A MX2017003808 A MX 2017003808A MX 2017003808 A MX2017003808 A MX 2017003808A MX 2017003808 A MX2017003808 A MX 2017003808A MX 2017003808 A MX2017003808 A MX 2017003808A
Authority
MX
Mexico
Prior art keywords
kynurenine
apc
presenting cells
antigen presenting
therapeutics
Prior art date
Application number
MX2017003808A
Other languages
English (en)
Inventor
Ghahary Aziz
B Jalili Reza
T Kilani Ruhangiz
Li Yunyuan
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of MX2017003808A publication Critical patent/MX2017003808A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)

Abstract

La invención proporciona combinaciones de quinurenina y células presentadoras de antígeno (APC) para modular tolerancia inmunitaria, en donde las combinaciones se pueden usar para modular una respuesta inmunitaria, que puede ser de uso en el tratamiento de diabetes tipo I (TID) o alopecia areata (AA) También se proporcionan usos de quinurenina y células presentadoras de antígeno (APC) como un modulador inmunitario para el tratamiento de TID o AA.
MX2017003808A 2014-09-26 2015-09-25 Una combinacion de quinurenina y celulas presentadoras de antigeno (apc) como productos terapeuticos y metodos para uso en modulacion inmunitaria. MX2017003808A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055823P 2014-09-26 2014-09-26
US201462087156P 2014-12-03 2014-12-03
PCT/CA2015/000506 WO2016044922A1 (en) 2014-09-26 2015-09-25 A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation

Publications (1)

Publication Number Publication Date
MX2017003808A true MX2017003808A (es) 2017-12-15

Family

ID=55579987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003808A MX2017003808A (es) 2014-09-26 2015-09-25 Una combinacion de quinurenina y celulas presentadoras de antigeno (apc) como productos terapeuticos y metodos para uso en modulacion inmunitaria.

Country Status (14)

Country Link
US (2) US20170209401A1 (es)
EP (1) EP3197466B1 (es)
JP (1) JP6898228B2 (es)
AU (1) AU2015321365B2 (es)
CA (1) CA2962655C (es)
CY (1) CY1124162T1 (es)
DK (1) DK3197466T3 (es)
ES (1) ES2867301T3 (es)
HU (1) HUE054020T2 (es)
MX (1) MX2017003808A (es)
PL (1) PL3197466T3 (es)
PT (1) PT3197466T (es)
RU (1) RU2727573C2 (es)
WO (1) WO2016044922A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190201360A1 (en) 2016-08-31 2019-07-04 Ampio Pharmaceuticals, Inc. Treatment of disease with n-acetyl kynurenine
US11712425B2 (en) 2018-03-14 2023-08-01 Albert Einstein College Of Medicine Immunoregulatory role of 3-OH-kynurenamine and uses thereof
CA3118682A1 (en) * 2018-11-04 2020-05-07 Figene, Llc Methods and compositions for treatment of type 1 diabetes using fibroblasts as facilitators of islet engraftment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
AU2002952834A0 (en) * 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
US8313894B2 (en) * 2008-07-01 2012-11-20 Genocea Biosciences, Inc. Antigen screening system
AU2009279787B2 (en) * 2008-08-04 2014-05-29 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ITRM20080529A1 (it) * 2008-10-07 2010-04-08 Uni Degli Studi Perugia Uso della l-chinurenina e suoi derivati per la prevenzione ed il trattamento del diabete mellito di tipo 1.
EP2593480A2 (en) * 2010-07-15 2013-05-22 Technion Research & Development Foundation Ltd. Antibodies with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012136815A1 (en) * 2011-04-08 2012-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Culture medium and method for obtaining a population of tolerogenic dendritic cells
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
JP2014111631A (ja) * 2014-01-31 2014-06-19 Tella Inc 樹状細胞の培養方法

Also Published As

Publication number Publication date
CA2962655C (en) 2022-08-09
JP6898228B2 (ja) 2021-07-07
AU2015321365A1 (en) 2017-04-20
RU2017114206A3 (es) 2019-04-30
EP3197466A4 (en) 2018-05-30
WO2016044922A1 (en) 2016-03-31
EP3197466B1 (en) 2021-02-17
PL3197466T3 (pl) 2021-09-13
US20230414550A1 (en) 2023-12-28
CY1124162T1 (el) 2022-05-27
RU2727573C2 (ru) 2020-07-22
US20170209401A1 (en) 2017-07-27
ES2867301T3 (es) 2021-10-20
DK3197466T3 (da) 2021-05-10
CA2962655A1 (en) 2016-03-31
RU2017114206A (ru) 2018-10-26
PT3197466T (pt) 2021-05-14
JP2017528508A (ja) 2017-09-28
HUE054020T2 (hu) 2021-08-30
AU2015321365B2 (en) 2021-05-20
EP3197466A1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
MX2021009309A (es) Modulacion de la actividad del complemento.
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2020014121A (es) Agonistas parciales del receptor de insulina.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
MX2015003874A (es) Modulacion de ire1.
MX2021015632A (es) Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
AU2018289493A1 (en) Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction
MX2015012334A (es) Metodos y composiciones para el control de malezas.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
MX2015011228A (es) Sales de glicopirrolato.
MX2019006527A (es) Moduladores de la actividad del complemento.
WO2016040824A3 (en) METHODS OF IDENTIFYING MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USE OF SAME TO MODULATE mTORC1
MA39835A (fr) Compositions et procédés de modulation de l'épissage du smn2 chez un patient
MX2020012893A (es) Formulaciones de proteinas.
EA201792456A1 (ru) Ферментёр для получения псевдопластической среды
MX2017003808A (es) Una combinacion de quinurenina y celulas presentadoras de antigeno (apc) como productos terapeuticos y metodos para uso en modulacion inmunitaria.
WO2018022844A3 (en) COMPOSITIONS AND METHODS FOR MODULATION OF FACTOR IX FUNCTION
WO2015170286A3 (en) Modulation of blood glucose levels
NZ765691A (en) Aryl receptor modulators and methods of making and using the same
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes